Melanoma & Skin Cancer

Anthony J. Olszanski, MD, RPh, discusses the treatment selection process for use of cemiplimab in patients with cutaneous squamous cell carcinoma.

New therapeutic approaches for treating patients with earlier-stage melanoma who face a higher risk of recurrence are among the features of recently updated consensus guidelines from the Society for Immunotherapy of Cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.

Keith T. Flaherty, MD, discussed the distinguishing features of the combination of encorafenib with binimetinib as well as some next steps, including the question of whether the regimen eventually could move to the adjuvant setting.

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses considerations for initial treatment of patients with metastatic melanoma.

Select patients with melanoma who consume a diet rich in fiber could see an improved response to treatment with immunotherapy.

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses unmet needs in melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone's Perlmutter Cancer Center, a 2016 Giant of Cancer Care in Melanoma, discusses the FDA approval of pembrolizumab for stage III melanoma.

The FDA has approved the PD-1 inhibitor pembrolizumab for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection.

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses the potential for combination immunotherapy and radiation in the treatment of patients with melanoma.

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high tumors, and 3 expanded uses in advanced non–small cell lung cancer.

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

The FDA has granted an accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

The European Commission has approved pembrolizumab as an adjuvant treatment for patients with resected, stage III melanoma with lymph node involvement.

The monoclonal anti-PD-1 antibody cemiplimab continued to demonstrate considerable antitumor activity and durable responses in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma.

Hussein A. Tawbi, MD, PhD, associate professor of medicine, The University of Texas MD Anderson Cancer Center, discusses evolving treatment for patients with melanoma.

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the inclusion of patients with brain metastases on melanoma clinical trials.

In an analysis of patient-reported outcomes of the JAVELIN Merkel 200 trial of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and patient-reported outcome endpoints.

An ongoing phase II study evaluating the PD-1 inhibitor cemiplimab in patients with basal cell carcinoma may prove efficacious based on its activity in other advanced malignancies.